Medico Remedies shareholders approve FY26 accounts, director reappointments
- Medico Remedies held its 32nd AGM on September 22, 2026, approving all seven resolutions
- Audited financial statements for FY26 adopted by requisite majority
- Haresh Kapurlal Mehta reappointed as director retiring by rotation
- Remuneration increases approved for Managing Director Harshit Mehta and other key personnel
- Only 34 members participated in the virtual meeting out of 16,439 record date holders
*this image is generated using AI for illustrative purposes only.
Medico Remedies held its 32nd Annual General Meeting (AGM) on September 22, 2026, via Video Conferencing. Shareholders adopted the audited financial statements for the fiscal year ended March 31, 2026, and approved key board reappointments.
The meeting was presided over by Haresh Mehta, Chairman and Whole-Time Director. Due to low attendance, only 34 members participated through the virtual platform. The notice convening the meeting and the Auditors' Report were taken as read, with statutory documents available for inspection.
Key resolutions passed
The AGM addressed both ordinary and special business items, focusing on leadership continuity and remuneration adjustments. The company disclosed that all seven resolutions were passed by requisite majority.
| Item | Description | Status |
|---|---|---|
| Financials | Adoption of audited FY26 financial statements | Approved |
| Rotation | Reappointment of Haresh Kapurlal Mehta (DIN: 01080289) | Approved |
| Special Business | Reappointment of Rishit Mehta as Whole-Time Director | Approved |
| Special Business | Reappointment of Haresh Mehta as Chairman & Whole-Time Director | Approved |
| Remuneration | Increase in pay for Harshit Mehta (Managing Director) | Approved |
| Professional Fees | Increase in fees for Priyal Rishit Mehta (Consultant) | Approved |
| Remuneration | Increase in pay for Shweta Harshit Mehta (Regulatory Deputy Manager) | Approved |
Voting participation and breakdown
The company disclosed specific voting data pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. A total of 16,439 shareholders were on the record date of September 15, 2026. Voting was conducted via remote e-voting and live e-voting during the meeting.
The scrutiny report highlighted significant promoter support across all resolutions. For the adoption of financial statements, promoters cast 50,937,145 votes in favour, while public non-institutional investors polled 167,626 votes, with only 13 votes against. In contrast, institutional public shareholders did not participate in the voting process for any resolution.
Operational overview and shareholder queries
During the session, the Chairman provided an overview of the company's operations and financial performance for FY26, along with its future outlook. Two registered shareholders raised questions regarding the status of operations at both existing and new manufacturing units. These queries were satisfactorily answered by the Chairman.
Compliance and scrutiny details
Ms. Shreya Shah, a Practicing Company Secretary, served as the Scrutinizer to supervise the e-voting process. The combined report on voting results from remote e-voting and live e-voting was submitted to stock exchanges and published on the company website within two working days of the meeting's conclusion. The meeting commenced at 4:00 pm and concluded at 4:15 pm, with e-voting remaining open for 15 minutes post-AGM.
Historical Stock Returns for Medico Remedies
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.09% | +2.08% | -40.27% | -42.05% | -56.13% | -8.55% |
How will the approved remuneration increases for key family members impact Medico Remedies' operating margins in the upcoming fiscal year?
What specific capacity expansion plans are underway for the new manufacturing units mentioned during shareholder queries?
Given the complete absence of institutional voting participation, what steps is the company taking to attract long-term institutional investors?
18
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
